Effect of adriamycin combined with metformin on biological function of human tongue cancer SSC-15 cells

Abstract

The effect of adriamycin (ADM) combined with metformin (MET) on the biological function of human tongue cancer SSC-15 cells was investigated. SCC-15 cells (ATCC ® CRL-1623) were cultured in vitro . The close concentration of the median lethal dose (LD50) of ADM was 0.05 mg/l and the LD50 of MET was 10 mmol/l after 48 h of intervention. They were used for drug combination experiments. Cells without drug treatment were used as the control group, cells treated with ADM alone, MET alone and their drug combination (ADM+MET) as the experimental groups. CCK-8 was used to detect the cell survival rate, and flow cytometry to detect the apoptosis rate in each group, Transwell chamber to detect the invasion ability in vitro of cells and scratch-healing experiment to observe the migration ability of the cells. The survival rate of tongue cancer SCC-15 cells gradually decreased with the increase in ADM and MET concentrations and in intervention time (P<0.05). The apoptosis rate in the ADM, MET and ADM+MET groups was significantly higher than that in the control group (P<0.05). The apoptosis rate in the ADM+MET group was higher than that in the ADM and MET groups (P<0.05). The invasion and migration ability of cells in the ADM and MET groups were higher than those in the ADM+MET group (P<0.05). The cell membrane number and the migration rate of cells in the ADM+MET group were significantly lower than those in the ADM and MET groups (P<0.05). Both MET and ADM inhibit the growth, invasion and migration of tongue cancer SSC-15 cells, and induce their apoptosis. Thus, ADM and MET in combination is more effective than ADM alone and MET alone in inhibiting the growth, invasion and migration of tongue cancer cells as well as in inducing their apoptosis.

Bridging the Gap: Exploring the Causal Relationship between Metformin and Tumors

“…A single-arm IIa clinical trial used metformin in 23 patients with oral precancerous lesions without T2D and found that the patients' pathology was greatly alleviated, which was closely related to metformin's inhibition of the mTOR signaling pathway [44]. In the study of metformin and tongue cancer, only one study showed that doxorubicin combined with metformin can inhibit the growth, invasion and migration of SSC-15 cells and promote SSC-15 cell apoptosis [45].…”